Vireo Growth Inc. and Curio Wellness Announce Manufacturing and Distribution Partnership
Vireo Growth Inc. (OTCQX: VREOF) has announced a strategic licensing partnership with Curio Wellness to manufacture and distribute Curio's Best Self Collection products in New York's cannabis market. The agreement enables Vireo to produce and distribute Curio's complete product portfolio, including topicals, tablets, chews, and vapes, using Vireo's existing New York infrastructure.
This capital-efficient growth strategy allows Curio to enter the New York market without significant investment, while Vireo expands its portfolio with Curio's GMP-certified, nationally recognized products. The partnership leverages Vireo's established presence in New York and Curio's reputation for quality and consistency in health and wellness cannabis products.
The companies expect to launch Curio-branded products in New York dispensaries in Q4 2025.
Vireo Growth Inc. (OTCQX: VREOF) ha annunciato una partnership strategica di licenza con Curio Wellness per la produzione e distribuzione dei prodotti della Best Self Collection di Curio nel mercato della cannabis di New York. L'accordo consente a Vireo di produrre e distribuire l'intero portafoglio prodotti di Curio, inclusi topici, compresse, caramelle e vaporizzatori, utilizzando le infrastrutture già esistenti di Vireo a New York.
Questa strategia di crescita efficiente in termini di capitale permette a Curio di entrare nel mercato di New York senza investimenti significativi, mentre Vireo amplia il proprio portafoglio con i prodotti certificati GMP e riconosciuti a livello nazionale di Curio. La partnership sfrutta la presenza consolidata di Vireo a New York e la reputazione di Curio per la qualità e la coerenza nei prodotti di cannabis per salute e benessere.
Le aziende prevedono di lanciare i prodotti a marchio Curio nelle dispensarie di New York nel quarto trimestre del 2025.
Vireo Growth Inc. (OTCQX: VREOF) ha anunciado una alianza estratégica de licencias con Curio Wellness para fabricar y distribuir los productos de la Best Self Collection de Curio en el mercado de cannabis de Nueva York. El acuerdo permite a Vireo producir y distribuir la cartera completa de productos de Curio, incluidos tópicos, tabletas, gomitas y vaporizadores, utilizando la infraestructura existente de Vireo en Nueva York.
Esta estrategia de crecimiento eficiente en capital permite a Curio ingresar al mercado de Nueva York sin una inversión significativa, mientras que Vireo amplía su portafolio con los productos certificados GMP y reconocidos a nivel nacional de Curio. La asociación aprovecha la presencia establecida de Vireo en Nueva York y la reputación de Curio por la calidad y consistencia en productos de cannabis para la salud y el bienestar.
Las empresas esperan lanzar productos con la marca Curio en dispensarios de Nueva York en el cuarto trimestre de 2025.
Vireo Growth Inc. (OTCQX: VREOF)는 Curio Wellness와 전략적 라이선스 파트너십을 체결하여 뉴욕 대마초 시장에서 Curio의 Best Self Collection 제품을 제조 및 유통한다고 발표했습니다. 이번 계약을 통해 Vireo는 기존 뉴욕 인프라를 활용하여 Curio의 전체 제품군인 국소제, 정제, 츄잉캔디, 베이프 등을 생산하고 유통할 수 있게 되었습니다.
이 자본 효율적인 성장 전략은 Curio가 큰 투자 없이 뉴욕 시장에 진입할 수 있도록 하며, Vireo는 GMP 인증을 받은 Curio의 전국적으로 인정받는 제품들로 포트폴리오를 확장할 수 있습니다. 이번 파트너십은 뉴욕에서 확립된 Vireo의 입지와 건강 및 웰니스 대마초 제품에서 품질과 일관성으로 인정받는 Curio의 명성을 활용합니다.
양사는 2025년 4분기에 뉴욕의 디스펜서리에 Curio 브랜드 제품을 출시할 계획입니다.
Vireo Growth Inc. (OTCQX : VREOF) a annoncé un partenariat stratégique de licence avec Curio Wellness pour fabriquer et distribuer les produits de la collection Best Self de Curio sur le marché du cannabis de New York. Cet accord permet à Vireo de produire et distribuer l'intégralité du portefeuille de produits de Curio, y compris les topiques, comprimés, gommes et vaporisateurs, en utilisant l'infrastructure existante de Vireo à New York.
Cette stratégie de croissance efficace en capital permet à Curio d'entrer sur le marché de New York sans investissement majeur, tandis que Vireo étend son portefeuille avec les produits certifiés GMP et reconnus au niveau national de Curio. Le partenariat tire parti de la présence établie de Vireo à New York et de la réputation de Curio pour la qualité et la cohérence de ses produits de cannabis santé et bien-être.
Les entreprises prévoient de lancer les produits sous la marque Curio dans les dispensaires de New York au quatrième trimestre 2025.
Vireo Growth Inc. (OTCQX: VREOF) hat eine strategische Lizenzpartnerschaft mit Curio Wellness angekündigt, um Curios Best Self Collection Produkte auf dem Cannabismarkt von New York herzustellen und zu vertreiben. Die Vereinbarung ermöglicht es Vireo, das vollständige Produktportfolio von Curio, einschließlich topischer Produkte, Tabletten, Kaubonbons und Vapes, unter Nutzung der bestehenden Infrastruktur von Vireo in New York zu produzieren und zu vertreiben.
Diese kapital-effiziente Wachstumsstrategie erlaubt es Curio, ohne große Investitionen in den New Yorker Markt einzutreten, während Vireo sein Portfolio mit Curios GMP-zertifizierten, national anerkannten Produkten erweitert. Die Partnerschaft nutzt Vireos etablierte Präsenz in New York sowie Curios Ruf für Qualität und Konsistenz bei Gesundheits- und Wellness-Cannabisprodukten.
Die Unternehmen planen, Curio-gebrandete Produkte im 4. Quartal 2025 in New Yorker Apotheken auf den Markt zu bringen.
- Capital-efficient expansion strategy requiring minimal investment
- Access to Curio's GMP-certified, nationally recognized product portfolio
- Leverages existing Vireo infrastructure in New York
- Entry into the growing New York cannabis market
- None.
-- Leading cannabis companies partner to leverage existing IP and brand value in New York --
CHICAGO and MINNEAPOLIS, July 01, 2025 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (“Vireo” or the “Company”) (CSE: VREO; OTCQX: VREOF), a multi-state, vertically-integrated cannabis operator, is pleased to announce a licensing agreement with Curio Wellness (“Curio”), a cGMP-certified, vertically-integrated cannabis company and market-leading innovator of health and wellness products. This strategic partnership will bring Curio’s celebrated Best Self Collection to the rapidly growing New York cannabis market.
Under the agreement, Vireo will have the ability to manufacture and distribute Curio’s full portfolio of products—including topicals, tablets, chews and vapes—leveraging Vireo’s existing infrastructure in New York. This capital-light growth model allows Curio to expand into one of the most promising markets in the country without the need for significant new investment, while Vireo enhances its portfolio with proven, high-demand offerings.
“We’re excited to bring Curio’s high-quality products to New York through this partnership,” said John Mazarakis, Chief Executive Officer of Vireo. “It’s a strong strategic fit that supports our focus on efficient growth and delivering premium offerings to our customers.”
Curio’s products have earned national recognition for both quality and consistency and are manufactured in compliance with Good Manufacturing Practices (GMP), ensuring they meet the stringent expectations of health-conscious cannabis consumers.
“This partnership is an exciting next step for our brand,” said Michael Bronfein, Chief Executive Officer of Curio Wellness. “Vireo has a strong track record in the New York market, and we’re confident they are the right partner to uphold the integrity of our products and deliver them to a broader audience.”
The first Curio-branded products are expected to launch in licensed New York dispensaries in Q4 2025.
About Curio Wellness
Curio Wellness is a cGMP-certified, vertically integrated cannabis company dedicated to developing, producing, and distributing innovative health and wellness products. Through science, integrity, and wellness-centered design, Curio empowers patients and adult-use consumers with trusted products that fit into a lifestyle of intention and care. For more information on Curio Wellness products, partnerships, and manufacturing efforts, please visit https://curiowellness.com.
About Vireo Growth Inc.
Vireo was founded in 2014 as a medical cannabis pioneer—and we’ve never stopped pushing boundaries. We’re building the most disciplined, strategically aligned, and execution-focused platform in the industry. That means staying relentlessly local while leveraging the strength of a national portfolio, backing exceptional leaders, and deploying capital and talent where it drives the most value. Vireo operates with a long-term mindset, a bias for action, and an unapologetic commitment to its customers, employees, shareholders, industry collaborators, and the communities it calls home. For more information about Vireo, visit www.vireogrowth.com.
Contact Information
Joe Duxbury
Chief Accounting Officer, Vireo Growth Inc.
investor@vireogrowth.com
(612) 314-8995
Wendy Bronfein
Chief Brand Officer, Curio Wellness
wendy.bronfein@curiowellness.com
Forward-Looking Statement Disclosure
This press release contains “forward-looking information” within the meaning of applicable United States and Canadian securities legislation. Forward-looking information contained in this press release may be identified by the use of words such as “should,” “believe,” “estimate,” “would,” “looking forward,” “may,” “continue,” “expect,” “expected,” “will,” “likely,” “subject to,” “transformation,” and “pending,” variations of such words and phrases, or any statements or clauses containing verbs in any future tense. These statements should not be read as guarantees of future performance or results. Forward-looking information includes both known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company or its subsidiaries to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements or information contained in this press release. Forward-looking information is based upon a number of estimates and assumptions of management, believed but not certain to be reasonable, in light of management’s experience and perception of trends, current conditions, and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment, and the availability of licenses, approvals and permits.
Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, the reader should not place undue reliance on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to: risks related to the achievement of management’s financial performance outlook, which may not be indicative of actual results, and risk factors set out in the Company’s Form 10-K for the year ended December 31, 2024 and the Company’s information statement regarding the Merger Transactions, both of which are available on EDGAR with the U.S. Securities and Exchange Commission and filed with the Canadian securities regulators and available under the Company’s profile on SEDAR+ at www.sedarplus.ca. The statements in this press release are made as of the date of this release. Except as required by law, we undertake no obligation to update any forward-looking statements or forward-looking information to reflect events or circumstances after the date of such statements.
FAQ
What products will Vireo Growth (VREOF) manufacture under the Curio Wellness partnership?
When will Curio Wellness products be available in New York through the Vireo partnership?
How does the Vireo-Curio partnership benefit both companies?
What is the significance of Curio's GMP certification in the cannabis industry?
What markets will the Vireo-Curio partnership serve?
